You are here

Home » CERID Bibliography

CERID Bibliography

Export 48 results:
[ Author(Desc)] Title Type Year
Filters: Keyword is Trypanosoma cruzi  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
B
Barrio AB, Van Voorhis WC, Basombrío MA. Trypanosoma cruzi: attenuation of virulence and protective immunogenicity after monoallelic disruption of the cub gene. Exp Parasitol. 2007 ;117(4):382-9.
Bressi JC, Verlinde CL, Aronov AM, Shaw ML, Shin SS, Nguyen LN, Suresh S, Buckner FS, Van Voorhis WC, Kuntz ID, et al. Adenosine analogues as selective inhibitors of glyceraldehyde-3-phosphate dehydrogenase of Trypanosomatidae via structure-based drug design. J Med Chem. 2001 ;44(13):2080-93.
Bressi JC, Choe J, Hough MT, Buckner FS, Van Voorhis WC, Verlinde CL, Hol WG, Gelb MH. Adenosine analogues as inhibitors of Trypanosoma brucei phosphoglycerate kinase: elucidation of a novel binding mode for a 2-amino-N(6)-substituted adenosine. J Med Chem. 2000 ;43(22):4135-50.
Buckner FS. Experimental chemotherapy and approaches to drug discovery for Trypanosoma cruzi infection. Adv Parasitol. 2011 ;75:89-119.
Buckner FS. Sterol 14-demethylase inhibitors for Trypanosoma cruzi infections. Adv Exp Med Biol. 2008 ;625:61-80.
Buckner FS, Bahia MTerezinha, Suryadevara PK, White KL, Shackleford DM, Chennamaneni NKumar, Hulverson MA, Laydbak JU, Chatelain E, Scandale I, et al. Pharmacological characterization, structural studies, and in vivo activities of anti-Chagas disease lead compounds derived from tipifarnib. Antimicrob Agents Chemother. 2012 ;56(9):4914-21.
Buckner FS, Joubert BM, Boyle SM, Eastman RT, Verlinde CLMJ, Matsuda SPT. Cloning and analysis of Trypanosoma cruzi lanosterol 14alpha-demethylase. Mol Biochem Parasitol. 2003 ;132(2):75-81.
Buckner FS, Verlinde CL, La Flamme AC, Van Voorhis WC. Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing beta-galactosidase. Antimicrob Agents Chemother. 1996 ;40(11):2592-7.
Buckner FS, Eastman RT, Nepomuceno-Silva JL, Speelmon EC, Myler PJ, Van Voorhis WC, Yokoyama K. Cloning, heterologous expression, and substrate specificities of protein farnesyltransferases from Trypanosoma cruzi and Leishmania major. Mol Biochem Parasitol. 2002 ;122(2):181-8.
Buckner FS, Wilson AJ, White TC, Van Voorhis WC. Induction of resistance to azole drugs in Trypanosoma cruzi. Antimicrob Agents Chemother. 1998 ;42(12):3245-50.
Buckner F, Yokoyama K, Lockman J, Aikenhead K, Ohkanda J, Sadilek M, Sebti S, Van Voorhis W, Hamilton A, Gelb MH. A class of sterol 14-demethylase inhibitors as anti-Trypanosoma cruzi agents. Proc Natl Acad Sci U S A. 2003 ;100(25):15149-53.
Buckner FS, Griffin JH, Wilson AJ, Van Voorhis WC. Potent anti-Trypanosoma cruzi activities of oxidosqualene cyclase inhibitors. Antimicrob Agents Chemother. 2001 ;45(4):1210-5.
Buckner FS, Wilson AJ, Van Voorhis WC. Trypanosoma cruzi: use of herpes simplex virus-thymidine kinase as a negative selectable marker. Exp Parasitol. 1997 ;86(3):171-80.
Buckner FS, Wilson AJ, Van Voorhis WC. Detection of live Trypanosoma cruzi in tissues of infected mice by using histochemical stain for beta-galactosidase. Infect Immun. 1999 ;67(1):403-9.
Buckner FS, Wipke BT, Van Voorhis WC. Trypanosoma cruzi infection does not impair major histocompatibility complex class I presentation of antigen to cytotoxic T lymphocytes. Eur J Immunol. 1997 ;27(10):2541-8.
Buckner FS, Navabi N. Advances in Chagas disease drug development: 2009-2010. Curr Opin Infect Dis. 2010 ;23(6):609-16.
C
Cetron MS, Basilio FP, Moraes AP, Sousa AQ, Paes JN, Kahn SJ, Wener MH, Van Voorhis WC. Humoral and cellular immune response of adults from northeastern Brazil with chronic Trypanosoma cruzi infection: depressed cellular immune response to T. cruzi antigen among Chagas' disease patients with symptomatic versus indeterminate infection. Am J Trop Med Hyg. 1993 ;49(3):370-82.
Cetron MS, Hoff R, Kahn S, Eisen H, Van Voorhis WC. Evaluation of recombinant trypomastigote surface antigens of Trypanosoma cruzi in screening sera from a population in rural northeastern Brazil endemic for Chagas' disease. Acta Trop. 1992 ;50(3):259-66.
Chennamaneni NKumar, Arif J, Buckner FS, Gelb MH. Isoquinoline-based analogs of the cancer drug clinical candidate tipifarnib as anti-Trypanosoma cruzi agents. Bioorg Med Chem Lett. 2009 ;19(23):6582-4.
D
Duthie MS, Cetron MS, Van Voorhis WC, Kahn SJ. Trypanosoma cruzi-infected individuals demonstrate varied antibody responses to a panel of trans-sialidase proteins encoded by SA85-1 genes. Acta Trop. 2005 ;93(3):317-29.
H
Hankins EG, Gillespie JR, Aikenhead K, Buckner FS. Upregulation of sterol C14-demethylase expression in Trypanosoma cruzi treated with sterol biosynthesis inhibitors. Mol Biochem Parasitol. 2005 ;144(1):68-75.
Hinshaw JC, Suh D-Y, Garnier P, Buckner FS, Eastman RT, Matsuda SPT, Joubert BM, Coppens I, Joiner KA, Merali S, et al. Oxidosqualene cyclase inhibitors as antimicrobial agents. J Med Chem. 2003 ;46(20):4240-3.
Hucke O, Gelb MH, Verlinde CLMJ, Buckner FS. The protein farnesyltransferase inhibitor Tipifarnib as a new lead for the development of drugs against Chagas disease. J Med Chem. 2005 ;48(17):5415-8.
J
Joubert BM, Buckner FS, Matsuda SP. Trypanosome and animal lanosterol synthases use different catalytic motifs. Org Lett. 2001 ;3(12):1957-60.
K
Kahn S, Van Voorhis WC, Eisen H. The major 85-kD surface antigen of the mammalian form of Trypanosoma cruzi is encoded by a large heterogeneous family of simultaneously expressed genes. J Exp Med. 1990 ;172(2):589-97.

Pages